Genome International Biomedical Co. Ltd. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced sales was TWD 11.845 million compared to TWD 19.987 million a year ago. Operating loss was TWD 4.179 million compared to TWD 3.513 million a year ago. Net loss was TWD 6.013 million compared to TWD 6.425 million a year ago. Basic loss per share was TWD 0.23 compared to TWD 0.24 a year ago. For the nine months, sales was TWD 43.091 million compared to TWD 65.697 million a year ago. Operating loss was TWD 13.708 million compared to TWD 11.819 million a year ago. Net loss was TWD 10.531 million compared to TWD 8.867 million a year ago. Basic loss per share was TWD 0.39 compared to TWD 0.33 a year ago.